- AmerisourceBergen Corporation (NYSE:ABC) announced the launch of its Cell and Gene Therapy (CGT) Integration Hub. This platform facilitates real-time data exchange to reduce potential barriers across the patient journey.
- The platform allows physicians to expedite their investigation process with real-time visibility into therapy and treatment development.
- Under the platform, AmerisourceBergen will offer support at each product lifecycle stage, including third-party logistics, regulatory consulting, and patient support services.
- "Our goal is to increase connectivity and reduce potential barriers across the patient journey," said Dale Hanna, Director of Cell & Gene Therapy Solutions at AmerisourceBergen.
- The company confirmed that it is on the verge of several landmark CGT approvals this year in the U.S., which reflects the rapid pace at which this sector is moving.
- Also Read: AmerisourceBergen, TPG To Acquire OneOncology From General Atlantic For $2.1B
- Price Action: ABC shares are up by 0.76% at $167.99 on the last check Monday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.